ADD/ADHD News

Low-income children with chronic conditions and their families could experience drastic cost increases for health care — as much as $233 to $2,472 in annual expenditures, depending on income levels and individual needs — if the Children’s Health Insurance Program is not renewed and the families are switched to Marketplace health insurance plans.

To mark our 30th anniversary, Infectious Diseases in Children will be examining some of the chronic conditions and infectious diseases that have impacted pediatric care over the past 3 decades.

Children who experienced racial discrimination were more likely to exhibit anxiety and depression, as well as an increased risk for attention deficit/hyperactivity disorder, according to research presented at the 2017 Pediatric Academic Societies Meeting.

Aevi Genomic Medicine recently presented updated responder data from the SAGA trial of AEVI-001, an oral nonstimulant, for adolescent ADHD.

Recent findings indicated dasotraline, a dopamine and norepinephrine reuptake inhibitor, significantly improved ADHD outcomes in the classroom among children aged 6 to 12 years.

Shire recently announced that Vyvanse is now available in the U.S. as a chewable tablet.

AEVI-001, an oral non-stimulant, did not meet its primary efficacy endpoint for ADHD, but did exhibit an encouraging trend in improvement at its highest dose, according to findings released by Aevi Genomic Medicine.

Parent-reported lifetime prevalence and comorbidity of asthma, attention deficit/hyperactivity disorder and autism spectrum disorder in children were differentially influenced by poverty status, according to recent study findings.

Shire recently announced that the FDA acknowledged receipt of a class 2 resubmission of a New Drug Application for SHP465, a triple-bead mixed amphetamine salts capsule, as a once-daily treatment for ADHD.

Sunovion Pharmaceuticals recently announced dasotraline, a dopamine and norepinephrine reuptake inhibitor, significantly improved ADHD in children aged 6 to 12 years.